Primary Objective:

• To determine the safety and tolerability of single and multiple ascending oral doses of CHR-5154 in healthy volunteers.

Secondary Objectives:

  • To determine the pharmacokinetic profile of CHR-5154 and its metabolite CHR-5426.
  • To compare the pharmacokinetic profile of CHR-5154 and CHR-5426 after a single dose of CHR-5154 in the fed and fasted state.

Read more: http://www.clinicaltrials.gov/ct2/show/NCT01934101?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30